[PDF][PDF] 中国鲍曼不动杆菌感染诊治与防控专家共识

陈佰义, 何礼贤, 胡必杰, 倪语星, 邱海波, 石岩, 施毅… - 2012 - img.medsci.cn
[编者按] 鲍曼不动杆菌已成为21 世纪临床重要致病茵. 鲍曼不动杆菌基因组研究发现其具有快速
获得和传播耐药性的能力, 多重耐药, 广泛耐药, 全耐药鲍曼不动杆菌已呈世界性流行 …

Managing Acinetobacter baumannii infections

J Garnacho-Montero, JF Timsit - Current opinion in infectious …, 2019 - journals.lww.com
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …

Microbiology of the skin and the role of biofilms in infection

SL Percival, C Emanuel, KF Cutting… - International wound …, 2012 - Wiley Online Library
The integrity of human skin is central to the prevention of infection. Acute and chronic
wounds can develop when the integrity of skin as a barrier to infection is disrupted. As a …

Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance

ZA Qureshi, LE Hittle, JA O'Hara… - Clinical infectious …, 2015 - academic.oup.com
Background. With an increase in the use of colistin methansulfonate (CMS) to treat
carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging …

Policy statement on antimicrobial stewardship by the society for healthcare epidemiology of America (SHEA), the infectious diseases society of America (IDSA), and …

N Fishman… - Infection Control & …, 2012 - cambridge.org
Antimicrobial resistance has emerged as a significant healthcare quality and patient safety
issue in the twenty-first century that, combined with a rapidly dwindling antimicrobial …

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

L Sorlí, S Luque, S Grau, N Berenguer, C Segura… - BMC infectious …, 2013 - Springer
Background Data regarding the most efficacious and least toxic schedules for the use of
colistin are scarce. The aim of this study was to determine the incidence and the potential …

Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria

M Bassetti, E Righi, A Vena, E Graziano… - Current opinion in …, 2018 - journals.lww.com
The exponential increase of antimicrobial resistance among virulent pathogens currently
represents one of the main challenges for clinicians in the intensive care unit. Knowledge of …

Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter baumannii in Mice

Y Hua, T Luo, Y Yang, D Dong, R Wang… - Frontiers in …, 2018 - frontiersin.org
Carbapenem-resistant Acinetobacter baumannii (CRAB) which is noted as a major
pathogen associated with healthcare-associated infections has steadily developed beyond …

Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis

K Kengkla, K Kongpakwattana… - Journal of …, 2018 - academic.oup.com
Objectives To comprehensively compare and rank the efficacy and safety of available
treatment options for patients with MDR and XDR Acinetobacter baumannii (AB) infection …

Task force on management and prevention of Acinetobacter baumannii infections in the ICU

J Garnacho-Montero, G Dimopoulos, G Poulakou… - Intensive care …, 2015 - Springer
Introduction Acinetobacter baumannii constitutes a dreadful problem in many ICUs
worldwide. The very limited therapeutic options available for these organisms are a matter of …